πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12037388

Anti-IL-33 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12030935

Anti-PDGF-B antibodies and pharmaceutical composition thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12029788

Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that i

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12024556

Anti-Staphylococcus antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12024570

Anti-CTLA-4 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12018087

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an o

Dyne Therapeutics, Inc. Β· Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12012444

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12013406

Methods of detecting anti-folic acid antibodies and uses thereof

The Board of Regents of the University of Texas System Β· Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12012445

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12012460

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an o

Dyne Therapeutics, Inc. Β· Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12012454

Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the sa

China Medical University Hospital Β· Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12006364

Anti-CD100 antibodies and methods for using the same

VACCINEX, INC. Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12006365

Human anti-semaphorin 4D antibody

VACCINEX, INC. Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12006363

Anti-tetraspanin 33 agents and compositions and methods for making and using the same

BioLegend, Inc. Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11999799

Anti-TMPRSS2 antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11999773

Anti-BCMA chimeric antigen receptors

Cartesian Therapeutics, Inc. Β· Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11999796

Anti-CD70 chimeric antigen receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11999777

Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11993655

Anti-PD-L1 antibody and use thereof

Oricell Therapeutics Co., Ltd. Β· Granted Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11993658

Anti-BCMA antibodies and treatment methods

Sutro Biopharma, Inc. Β· Granted Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11993573

Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroa

The Board of Regents for Oklahoma State University Β· Granted Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11981730

Anti-CXCL13 antibodies and methods of using the same

VACCINEX, INC. Β· Granted Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11981741

Humanized anti-CD45 antibodies

Actinium Phamaceuticals, Inc. Β· Granted Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11976122

Anti-IL13RΞ±2 antibodies

ADC THERAPEUTICS SA Β· Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted